The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

New Age Spa Institute

DECEMBER 18, 2024

We frequently receive inquiries about the exciting field of medical aesthetics! The Clinical Aesthetics Certification is 70 hours of continuing education units (CEU) and ideal for professionals aiming to work in medical spas, dermatology clinics, or with advanced skincare treatments. </p>

Medical 52

Medical Esthetics Legal Continuing Education 52

The Dermatology Digest

NOVEMBER 20, 2024

Bimekizumab, an interleukin 17F (IL-17F) and IL-17A blocker, is now the third medication approved for HS, joining adalimumab (Humira, AbbVie) and its biosimilars and secukinumab (Cosentyx, Novartis). The safety profile of bimekizumab was consistent with safety data seen in previous trials across indications with no new safety signals.

Safety 78

Safety Sustainability Clinic Medical 78

The Dermatology Digest

OCTOBER 16, 2024

Due to Dr. Gross’s work, Georgia is taking proactive steps to accurately define “cosmetic laser services” and ensuring these medical procedures are considered the practice of medicine to best protect patients. We appreciate their hard work and dedication to promoting and protecting patient safety.

Safety 36

Safety Surgery Office Dermatology 36

The Dermatology Digest

DECEMBER 13, 2024

This approval is based on positive results from the phase III ARCADIA clinical trial program which evaluated the efficacy and safety of nemolizumab in combination with background TCS, with or without TCI, versus placebo in combination with TCS, with or without TCI, in 1,728 patients aged 12 or older with moderate to severe atopic dermatitis.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. Ch’en, a medical student at the Albert Einstein College of Medicine in the Bronx, New York, and Peter A. The study appears in Dermatitis.

Treatments 77

Treatments Dermatitis Therapy Medical 77

The Dermatology Digest

MARCH 18, 2024

If approved, we believe that DFD-29 will be the only oral medication to address both inflammatory lesions and erythema from rosacea, and will be a preferred treatment option by physicians and their patients to address the condition.”

Rosacea 74

Rosacea Medical Office Clinic 74

The Dermatology Digest

FEBRUARY 11, 2024

By Ted Rosen, MD According to the results of a recently published investigation in JAMA Dermatology 1 , the Janus kinase (JAK) inhibitors currently utilized for a variety of skin diseases appear safe in our dermatological population. Ireland PA, Jansson N, Spencer SKR. January 31, 2024. doi:10.1001/jamadermatol.2023.5509

Dermatology 74

Dermatology Safety Clinic Therapy 74

The Dermatology Digest

JANUARY 29, 2024

The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a parallel group, double-blind, vehicle-controlled study evaluating the safety and efficacy of Zoryve (roflumilast) foam, 0.3% Zoryve foam was well-tolerated with a favorable safety and tolerability profile.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

FEBRUARY 2, 2024

New sunscreen ingredients are needed to help assuage patient safety concerns and lower skin cancer rates. Natural products such as algae and herb derivatives are also gaining traction, according to a new narrative review in the Journal of Integrative Dermatology. What’s New in ‘Natural’ Sunscreens?

Ingredients 74

Ingredients Safety Innovations Dermatology 74

The Dermatology Digest

AUGUST 20, 2024

There are currently no other FDA-approved oral medications for moderate to severe plaque psoriasis in this patient population. The adverse events were consistent with the known safety profile of Otezla in adult patients. sPGA response for Otezla versus 10.8% for placebo (95% CI: 12.2%, 32.4%. For more information, visit Otezla.com.

Safety 74

Safety Injections Therapy Treatments 74

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 80

Retinol Social Media Skincare Routine Skincare 80

The Dermatology Digest

FEBRUARY 14, 2024

“We are thankful to the patients and medical experts whose insights informed our clinical trials, which assessed nemolizumab’s ability to reduce the symptoms of itch and skin lesions. Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

JANUARY 5, 2024

Journey Medical Corporation has submitted a New Drug Application (NDA) to the U.S. The NDA submission is based on positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea. The post Rosacea Pipeline Watch: Journey Medical Submits NDA for DFD-29 appeared first on The Dermatology Digest.

Rosacea 36

Rosacea Medical Office Safety 36

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. The post Eye on Itch: Evommune Initiaties Phase I Study of EVO756 in CSU appeared first on The Dermatology Digest. ” More About EVO756 MRGPRX2 is most abundantly found on mast cells and peripheral sensory neurons.

Safety 74

Safety Office Dermatitis Clinic 74

Academic Alliance in Dermatology

FEBRUARY 13, 2024

At Academic Alliance in Dermatology, we understand the importance of using products that not only care for your skin on the surface but also work effectively at a cellular level. This is where medical-grade skincare like SkinCeuticals, ZO, Colorescience, Obagi, SkinMedica and Alastin distinctly outshine drugstore brands.

Medical Grade Skincare 36

Medical Grade Skincare Medical Skincare Skin Health 36

Academic Alliance in Dermatology

FEBRUARY 13, 2024

At Academic Alliance in Dermatology, we understand the importance of using products that not only care for your skin on the surface but also work effectively at a cellular level. This is where medical-grade skincare like SkinCeuticals, ZO, Colorescience, Obagi, SkinMedica and Alastin distinctly outshine drugstore brands.

Medical Grade Skincare 36

Medical Grade Skincare Medical Skincare Skin Health 36

The Dermatology Digest

SEPTEMBER 23, 2024

These trials evaluated the safety and efficacy of delgocitinib compared to cream vehicle. This news is testament to our dedication to making a fundamental difference for those who need us most in medical dermatology. Both trials met their primary and all secondary endpoints. with the same determination and dedication.”

Eczema 66

Eczema Safety Dermatology Clinic 66

Texas Dermatology

OCTOBER 20, 2023

However, it’s crucial to prioritize safety when applying makeup to your skin. In this blog, we’ll discuss Halloween makeup safety tips, what to do if you encounter a bad skin reaction, and why scheduling a dermatology appointment at Texas Dermatology is essential for addressing skin issues.

Makeup 36

Makeup Safety Skin Issues Irritation 36

West Lake Dermatology

SEPTEMBER 24, 2024

In the ever-evolving world of weight loss treatments, GLP-1 agonists like semaglutide (the active ingredient in popular medications like Ozempic or Wegovy) and tirzepatide (the active ingredient in Mounjaro) have rapidly gained popularity. of their body weight over 68 weeks, compared to just 2.4% in the placebo group.

Medical 36

Medical Diet Safety Sustainability 36

The Dermatology Digest

MARCH 5, 2024

Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the second half of 2024. The post And Then There Were Six…FDA Green Lights Hugel’s Toxin for Glabellar Lines appeared first on The Dermatology Digest. and Europe.

Branding 74

Branding Injections Safety Facials 74

The Dermatology Digest

JANUARY 14, 2024

The research was presented at the 2024 Winter Clinical Dermatology Conference – Hawaii in Honolulu. Treatment with Zoryve foam significantly increased the odds of achieving a meaningful improvement in quality of life at Weeks 2, 4, and 8, compared to vehicle as measured by the Dermatology Life Quality Index (DLQI), the study showed.

Dermatitis 72

Dermatitis Dermatology Office Safety 72

The Dermatology Digest

AUGUST 13, 2024

” The Crnic Institute study team is now overseeing a second trial testing the safety and efficacy of the JAK inhibitor relative to other medicines for treating the condition known as Down Syndrome Regression Disorder , and a third trial focused on children with Down syndrome is expected to start recruitment in late 2024. .”

Clinic 74

Clinic Safety Dermatitis Medical 74

The Dermatology Digest

SEPTEMBER 20, 2024

Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s Secondary efficacy objectives include progression-free survival, overall survival and local control up to twelve months after treatment, and the safety objective is the measurement of any related adverse events. Dr. Robert B.

Office 74

Office Safety Clinic Medical 74

The Dermatology Digest

JUNE 18, 2024

Permanent makeup can help restore confidence in people with certain skin and hair conditions, according to a new article in the Journal of the American Academy of Dermatology. In South Carolina, permanent makeup is regulated by the state’s medical board.

Permanent Makeup 36

Permanent Makeup Makeup Sanitation and Sterilization Dermatology 36

The Dermatology Digest

MARCH 12, 2024

may help treat milder hidradenitis suppurativa (HS), according to new phase 2 data presented at the annual meeting of the American Academy of Dermatology in San Diego, CA. Porter, MD, a dermatologist at Beth Israel Deaconess Medical Center in Boston, tells TDD. Twice-daily application of ruxolitinib (Opzelura, Incyte) cream, 1.5%

Therapy 69

Therapy Safety Dermatology Treatments 69

The Dermatology Digest

MARCH 5, 2024

The Allergan Medical Institute (AMI) team can train aesthetic providers on safe and effective treatments using the Allergan Aesthetics portfolio to address 90% of the face. The post FDA Approves JUVÉDERM VOLUMA XC for Filling Temple Hollows appeared first on The Dermatology Digest.

Portfolios 74

Portfolios Injections Training Facials 74

Alison Bladh

JANUARY 1, 2025

Medical and Cosmetic Solutions Platelet-Rich Plasma (PRP) Therapy : This treatment involves injecting your plasma into the brow area to stimulate hair growth. Journal of the American Academy of Dermatology. Dermatologic Therapy. Journal of Cosmetic Dermatology. Dermatology Clinics. Dermatology Clinics.

Treatments 52

Treatments Skincare Routine Hydration Therapy 52

The Dermatology Digest

DECEMBER 4, 2024

Restem’s ULSC therapy has shown promising results in early clinical trials, demonstrating safety, tolerability and initial clinically significant improvements, as well as the potential to significantly reduce the need for steroid use in patients. The company is currently preparing for Phase 2/3 trials with anticipated initiation in 1Q 2025.

Treatments 36

Treatments Office Therapy Clinic 36

The Dermatology Digest

DECEMBER 20, 2023

Secondary measures of efficacy, as well as safety and pharmacokinetics, will also be assessed. Head of the SAB, Is a Professor of Dermatology with Penn State Health Hershey Medical Center, and Penn State College of Medicine. is a Professor of Dermatology and Director of Dermatologic Surgery at the University of Minnesota.

Dermatology 36

Dermatology Surgery Eczema Office 36

The Dermatology Digest

SEPTEMBER 9, 2024

Obagi Introduces Two New Elastiderm Products Obagi Medical is launching Elastiderm Lift Up & Sculpt Facial Moisturizer and Elastiderm Advanced Filler Concentrate. The post TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology in the U.S.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

JUNE 12, 2024

The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals. The post Tox Update: Evolus Launches Nuceiva in Spain appeared first on The Dermatology Digest. Evolus, Inc. is rolling out Nuceiva (botulinum toxin type A) across Spain.

Safety 36

Safety Branding Facials Clinic 36

US Dermatologt Partners

JUNE 1, 2024

1 In an interview with Dermatology Times, Lockshin explained how far we have come in oral treatment options for psoriasis, the future outlook, and patient populations that benefit most from orals. A study involving 245 patients showed significant improvements at 16 weeks, confirming its efficacy and safety in younger populations.6

Therapy 41

Therapy Injections Safety Management 41

North Dallas Dermatology Associates

NOVEMBER 1, 2023

After all, who wouldn’t want to be in the capable hands of a medical professional? While practitioners in medical spas and salons may offer discounted rates, there is often a concerning lack of specialized training. This added layer of safety provides peace of mind to patients.

Office 36

Office Safety Medical Training 36

The Dermatology Digest

NOVEMBER 18, 2024

Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. ” Comprehensive results from both ICONIC-LEAD and ICONIC-TOTAL are being prepared for presentation at upcoming medical congresses and will be shared with health authorities in planned submissions. achieving PASI-90.

Safety 36

Safety Innovations Medical Dermatology 36

The Dermatology Digest

NOVEMBER 30, 2024

Lipella has received an Investigational New Drug (IND) approval for a Phase 2a multicenter dose-escalation trial evaluating the safety and efficacy of LP-10 in subjects with symptomatic OLP. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus. Stay tuned.

Pharmaceutical 36

Pharmaceutical Safety Marketing Therapy 36

The Dermatology Digest

MAY 23, 2024

Kimball, MD, MPH, Beth Israel Deaconess Medical Center and Professor of Dermatology, Harvard Medical School, Boston, MA. “In The safety profile of bimekizumab was consistent with safety data seen in previous trials with no new observed safety signals. Responses were maintained to Week 48.

Sustainability 36

Sustainability Safety Clinic Medical 36